147081-29-6 Usage
Description
(S)-4-N-Boc-2-methylpiperazine, also known as (S)-4-Boc-2-methylpiperazine, is a colorless to yellow liquid that serves as a versatile reagent in the field of organic chemistry. It is primarily used in the synthesis of various biologically active molecules and pharmaceutical compounds due to its unique chemical properties.
Uses
Used in Pharmaceutical Synthesis:
(S)-4-N-Boc-2-methylpiperazine is used as a reagent for the synthesis of benzamide peptidomimetic as non-ATP competitive inhibitors. These inhibitors play a crucial role in the development of drugs targeting various diseases and conditions.
Used in the Synthesis of Biologically Active Molecules:
(S)-4-N-Boc-2-methylpiperazine is used as a reactant in the synthesis of several biologically active molecules, including:
1. CCR5 antagonists with anti-HIV-1 activity: These antagonists are essential in the development of antiretroviral drugs to combat HIV-1 infection.
2. Opioid receptor antagonists: These molecules are vital in the treatment of opioid addiction and related disorders.
3. Human growth hormone secretagogue receptor antagonists: These antagonists are used in the treatment of obesity by modulating the growth hormone secretion.
4. Fatty acid oxidation inhibitors: These inhibitors are employed in the development of drugs targeting metabolic disorders related to fatty acid metabolism.
Used in Laboratory Chemicals:
(S)-4-N-Boc-2-methylpiperazine is also utilized as a laboratory chemical, providing researchers with a valuable tool for conducting experiments and developing new compounds.
Used in the Manufacture of Substances:
Furthermore, (S)-4-N-Boc-2-methylpiperazine is used in the manufacturing process of various substances, contributing to the production of pharmaceuticals, chemicals, and other related products.
Check Digit Verification of cas no
The CAS Registry Mumber 147081-29-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,0,8 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 147081-29:
(8*1)+(7*4)+(6*7)+(5*0)+(4*8)+(3*1)+(2*2)+(1*9)=126
126 % 10 = 6
So 147081-29-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N2O2/c1-8-7-12(6-5-11-8)9(13)14-10(2,3)4/h8,11H,5-7H2,1-4H3/t8-/m0/s1
147081-29-6Relevant articles and documents
TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
-
Paragraph 00293; 00351, (2019/07/13)
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Development of an Efficient Manufacturing Process for Reversible Bruton's Tyrosine Kinase Inhibitor GDC-0853
Zhang, Haiming,Cravillion, Theresa,Lim, Ngiap-Kie,Tian, Qingping,Beaudry, Danial,Defreese, Jessica L.,Fettes, Alec,James, Philippe,Linder, David,Malhotra, Sushant,Han, Chong,Angelaud, Remy,Gosselin, Francis
, p. 978 - 990 (2018/07/15)
Efforts toward the process development of reversible Bruton's tyrosine kinase (BTK) inhibitor GDC-0853 (1) are described. A practical synthesis of GDC-0853 was accomplished via a key highly regioselective Pd-catalyzed C-N coupling of tricyclic lactam 5 with 2,4-dichloronicotinaldehyde (6) to afford the C-N coupling product 3, a Suzuki-Miyaura cross-coupling of intermediate 3 with boronic ester 4 derived from a Pd-catalyzed borylation of tetracyclic bromide 7, to generate penultimate aldehyde intermediate 2 and subsequent aldehyde reduction and recrystallization. Process development of starting materials 5, 6, and 7 is also discussed.
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
-
Paragraph 1665; 1666, (2016/02/21)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.